Cough, Cold and Allergy (Hay Fever) Remedies in Australia
November 15, 2022
Euromonitor
26
PDF
Cough, Cold and Allergy (Hay Fever) Remedies in Australia
Abstract Cough, cold and allergy (hay fever) remedies is set to record higher current value growth in 2022, primarily driven by the return of an unusually strong influenza season in Australia. At the beginning of the year and during the pandemic, the occurrence of flu was 236 times lower than the review period average. Nevertheless, the reopening of Australia’s border in late February 2022 (introducing new strains of flu from other countries) and the low uptake of flu vaccinations are resulting in a spik...
Euromonitor International's Cough, Cold and Allergy (Hay Fever) Remedies in Australia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report? * Get a detailed picture of the Cough, Cold and Allergy (Hay Fever) Remedies market; * Pinpoint growth sectors and identify factors driving change; * Understand the competitive environment, the market’s major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop.
Content Cough, Cold and Allergy (Hay Fever) Remedies in Australia January 2023
List Of Contents And Tables
COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES IN AUSTRALIA KEY DATA FINDINGS 2022 DEVELOPMENTS Strong demand for combination products - cough, cold and allergy (hay fever) remedies due to surge in influenza cases Free vaccine rollout to ramp up influenza vaccination rates Johnson & Johnson strengthens leadership of cough, cold and allergy (hay fever) remedies in 2022 PROSPECTS AND OPPORTUNITIES New product development expected to drive sales of cough, cold and allergy (hay fever) remedies Stable demand for antihistamines/allergy remedies in line with greater mobility and climate change CATEGORY DATA Table 1 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2017-2022 Table 2 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2017-2022 Table 3 NBO Company Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2018-2022 Table 4 LBN Brand Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2019-2022 Table 5 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2022-2027 Table 6 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2022-2027 CONSUMER HEALTH IN AUSTRALIA EXECUTIVE SUMMARY Consumer health in 2022: The big picture 2022 key trends Competitive landscape Retailing developments What next for consumer health? MARKET INDICATORS Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022 Table 8 Life Expectancy at Birth 2017-2022 MARKET DATA Table 9 Sales of Consumer Health by Category: Value 2017-2022 Table 10 Sales of Consumer Health by Category: % Value Growth 2017-2022 Table 11 NBO Company Shares of Consumer Health: % Value 2018-2022 Table 12 LBN Brand Shares of Consumer Health: % Value 2019-2022 Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022 Table 14 Distribution of Consumer Health by Format: % Value 2017-2022 Table 15 Distribution of Consumer Health by Format and Category: % Value 2022 Table 16 Forecast Sales of Consumer Health by Category: Value 2022-2027 Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027 APPENDIX OTC registration and classification Vitamins and dietary supplements registration and classification Self-medication/self-care and preventive medicine Switches Summary 1 OTC: Switches 2021-2022 DISCLAIMER DEFINITIONS SOURCES Summary 2 Research Sources
Cough, cold and allergy (hay fever) remedies is set to record higher current value growth in 2022, primarily driven by the return of an unusually strong influenza season in Australia. At the beginning of the year and during the pandemic, the occurrence of flu was 236 times lower than the review period average. Nevertheless, the reopening of Australia’s border in late February 2022 (introducing new strains of flu from other countries) and the low uptake of flu vaccinations are resulting in a spik...
Euromonitor International's Cough, Cold and Allergy (Hay Fever) Remedies in Australia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report? * Get a detailed picture of the Cough, Cold and Allergy (Hay Fever) Remedies market; * Pinpoint growth sectors and identify factors driving change; * Understand the competitive environment, the market’s major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop.
Cough, Cold and Allergy (Hay Fever) Remedies in Australia January 2023
List Of Contents And Tables
COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES IN AUSTRALIA KEY DATA FINDINGS 2022 DEVELOPMENTS Strong demand for combination products - cough, cold and allergy (hay fever) remedies due to surge in influenza cases Free vaccine rollout to ramp up influenza vaccination rates Johnson & Johnson strengthens leadership of cough, cold and allergy (hay fever) remedies in 2022 PROSPECTS AND OPPORTUNITIES New product development expected to drive sales of cough, cold and allergy (hay fever) remedies Stable demand for antihistamines/allergy remedies in line with greater mobility and climate change CATEGORY DATA Table 1 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2017-2022 Table 2 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2017-2022 Table 3 NBO Company Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2018-2022 Table 4 LBN Brand Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2019-2022 Table 5 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2022-2027 Table 6 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2022-2027 CONSUMER HEALTH IN AUSTRALIA EXECUTIVE SUMMARY Consumer health in 2022: The big picture 2022 key trends Competitive landscape Retailing developments What next for consumer health? MARKET INDICATORS Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022 Table 8 Life Expectancy at Birth 2017-2022 MARKET DATA Table 9 Sales of Consumer Health by Category: Value 2017-2022 Table 10 Sales of Consumer Health by Category: % Value Growth 2017-2022 Table 11 NBO Company Shares of Consumer Health: % Value 2018-2022 Table 12 LBN Brand Shares of Consumer Health: % Value 2019-2022 Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022 Table 14 Distribution of Consumer Health by Format: % Value 2017-2022 Table 15 Distribution of Consumer Health by Format and Category: % Value 2022 Table 16 Forecast Sales of Consumer Health by Category: Value 2022-2027 Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027 APPENDIX OTC registration and classification Vitamins and dietary supplements registration and classification Self-medication/self-care and preventive medicine Switches Summary 1 OTC: Switches 2021-2022 DISCLAIMER DEFINITIONS SOURCES Summary 2 Research Sources